1-cyclopentyl-6-[(3S,4S)-4-methyl-1-(quinoxalin-6-ylmethyl)pyrrolidin-3-yl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one | 1082743-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-cyclopentyl-6-[(3S,4S)-4-methyl-1-(quinoxalin-6-ylmethyl)pyrrolidin-3-yl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: PF-4181366；1-cyclopentyl-6-[(3S,4S)-4-methyl-1-(quinoxalin-6-ylmethyl)pyrrolidin-3-yl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
• CAS: 1082743-32-5
• 化学式: C₂₄H₂₇N₇O
• 分子量: 429.525
• InChiKey: SNCRCEGCQVMUBS-DNVCBOLYSA-N

物化性质

• 沸点：
  643.2±65.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  88.3
• 氢给体数：
  1
• 氢受体数：
  6

制备方法与用途

这是一种强效、选择性的脑渗透型PDE9A抑制剂，其IC50值为1.8纳摩尔。

反应信息

• 作为产物：
  描述：

  1-cyclopentyl-6-[(3S,4S)-4-methylpyrrolidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 、 喹喔啉-6-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 4.0h， 以68%的产率得到1-cyclopentyl-6-[(3S,4S)-4-methyl-1-(quinoxalin-6-ylmethyl)pyrrolidin-3-yl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy

  摘要：

  By use of chemical enablement and prospective design, it novel series of selective, brain penetrant PDE9A inhibitors have been identified that are capable of producing in vivo elevations of brain cGMP.

  DOI：

  10.1021/jm9015334

文献信息

• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Verhoest Patrick R.

  公开号：US20090030003A1

  公开（公告）日：2009-01-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  该发明提供了式（I）的PDE9抑制化合物及其药用盐，其中R、R1、R2和R3如本文所定义。还提供了含有式I化合物的药物组合物，并将其用于治疗神经退行性和认知障碍，如阿尔茨海默病和精神分裂症。
• Pyrazolo[3,4-d]pyrimidine compounds
  申请人：Pfizer Inc.

  公开号：US07964607B2

  公开（公告）日：2011-06-21

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  本发明提供了PDE9抑制化合物的公式（I），以及其药学上可接受的盐，其中R，R1，R2和R3的定义如本文所述。还提供了含有公式I化合物的药物组合物，并用于治疗神经退行性和认知障碍，例如阿尔茨海默病和精神分裂症的用途。
• US7964607B2
  申请人：——

  公开号：US7964607B2

  公开（公告）日：2011-06-21
• [EN] AMINO-HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS AMINO-HÉTÉROCYCLIQUES
  申请人：PFIZER

  公开号：WO2008139293A1

  公开（公告）日：2008-11-20

  [EN] The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R₁, R₂ and R₃ are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
  [FR] L'invention porte sur des composés inhibant PDE9 de Formule (I) et sur des sels pharmaceutiquement acceptables de ceux-ci, où R, R₁, R₂ et R₃ sont tels que définis présentement. L'invention porte également sur des compositions pharmaceutiques contenant les composés de Formule I et sur les utilisations de celles-ci dans le traitement de troubles neurodégénératifs et cognitifs, tels que la maladie d'Alzheimer et la schizophrénie.
• Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy
  作者：Patrick R. Verhoest、Caroline Proulx-Lafrance、Michael Corman、Lois Chenard、Christopher J. Helal、Xinjun Hou、Robin Kleiman、Shenping Liu、Eric Marr、Frank S. Menniti、Christopher J. Schmidt、Michelle Vanase-Frawley、Anne W. Schmidt、Robert D. Williams、Frederick R. Nelson、Kari R. Fonseca、Spiros Liras

  DOI：10.1021/jm9015334

  日期：2009.12.24

  By use of chemical enablement and prospective design, it novel series of selective, brain penetrant PDE9A inhibitors have been identified that are capable of producing in vivo elevations of brain cGMP.